PARP1 and telomere syndrome: By contrast, low PARP1 expression is mostly found in LPS and MFS (77). A multicenter, randomized, controlled phase II clinical study (TOMAS2) explored the efficacy of trabectedin combined with the PARP inhibitor olaparib versus trabectedin alone in 130 adult patients with STS whose previous treatments had failed.